Small Cap ‘Breakthrough Technologies’ Track

  • The Breakthrough Technologies Conference, a new component of the bi-annual OneMedForum, is an invitation-only event that highlights exceptional companies developing new paradigms in therapeutics, devices, or diagnostic technology.

    The event aims to connect investors to small-cap companies with potential for extraordinary returns within 12 months of the conference. Selection of presenting companies is heavily weighted on an assessment of management, product potential, and near-term catalysts that drive value-creation for shareholders.

    NeoStem 8:00 AM
    (NBS)
    NeoStem, Inc. is a leader in the emerging cellular therapy industry. The company’s business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization (“CDMO”) providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

    Response Bio 8:20AM
    (RBM)
    Response Biomedical Corp., based in Vancouver, Canada, was founded in 1992. Response develops, manufactures and markets rapid on-site diagnostic tests at its world class manufacturing facility in Vancouver, Canada, for use on the RAMPA® Platform. The RAMPA® Platform is sold worldwide and includes a variety of testing applications in the clinical, infectious disease, biodefense and environmental arenas. The RAMPA® Platform provides laboratory quality results with the speed, precision and accuracy that many hospitals expect of their central lab systems. It is ideally suited for both point of care testing and laboratory use. The RAMP® Platform consists of a reader and single-use disposable test cartridges and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories.

    Synthetic Biologics 8:40AM
    (SYN)
    Synthetic Biologics, Inc., is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis.

    Nanoviricides 9:00 AM & 2:50 PM
    (NNVC)
    NanoViricides is developing broad-spectrum anti-influenza drugs as part of its rich drug pipeline. The Company believes that its FluCide drug candidates will be effective against most if not all influenza viruses, including the H7N9 bird flu, H3N2 or H1N1 epidemic viruses, H5N1 bird flu, seasonal influenzas, as well as novel influenza viruses. This is because FluCide is based on the Company’s biomimetic technology, mimicking the natural sialic acid receptors for the influenza virus on the surface of a nanoviricide® polymeric micelle. It is important to note that all influenza viruses bind to the sialic acid receptors, even if they rapidly mutate. The FluCide drug candidates have already shown strong effectiveness against H1N1 and H3N2 influenza viruses in highly lethal animal models. In addition, earlier candidates were shown to be effective against two different strains of H5N1 viruses in cell cultures. In a highly lethal animal model, the injectable FluCide drug candidates have shown 1,000X greater viral load reduction as compared to oseltamivir (Tamiflu®), the current standard of care. The small animal serves only as a test tube because FluCide is designed to attack the influenza virus directly and does not depend upon the host or its defenses. Thus the Company believes that these animal model results should translate readily into humans. NanoViricides has also developed an oral drug candidate against influenza. This oral version is also dramatically more effective than TamiFlu in the animals given a lethal influenza virus infection. This oral FluCide may be the very first nanomedicine that is effective when taken by mouth. In addition, NanoViricides has developed drug candidates against Dengue, HIV/AIDS, Herpes, and Ocular Viral Diseases that have shown strong effectiveness in relevant animal and/or cell culture models.

    Trovagene 9:20 AM
    (TROV)
    Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine. Trovagene is leveraging its intellectual property in oncogene mutations via out-licensing and use of its transrenal technologies to extend oncogene mutation detection using urine as a sample. As a non-invasive and abundant sample, urine may overcome many of the cost and collection challenges associated with biopsy, as well as the volume limitations of blood.

    Inovio Pharmaceuticals 9:40 AM
    (INO)
    Inovio is focused on the design, development, and delivery of DNA vaccines to prevent and treat cancers and infectious diseases. Its SynCon(TM) technology enables the design of “universal” vaccines capable of protecting against known and emergent, unknown pathogen strains. Its electroporation delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses. Inovio’s clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine.

    Del Mar Pharmaceuticals 10:00 AM
    (DMPI)
    Vancouver-based public company developing cancer therapeutics with substantially proven efficacy, for novel orphan drug indications. The company’s primary product candidate, VAL-083, is a first-in-class cancer therapeutic that has been tested in over 40 different clinical trials and has shown efficacy in the treatment of solid tumors, and Del Mar is expanding its indication for the treatment of glioblastoma multiforme, the most common and aggressive form of brain cancer. VAL-083 is approved for Chronic Myelogenous Leukemia and lung cancer in China.

    LabStyle Innovations 10:20 AM
    (DRIO)
    LabStyle Innovations Corp, a leader in mHealth (Mobile Health) is commercializing a patent-pending medical device technology technology that enables consumers to manage diabetes in a distinctive, easy-to-use way through the use of smartphones such as iPhones and Androids, and other mobile devices. LabStyle’s initial product is Dario, a stylish, easy-to-use medical device and software system addressing the market for patient self-monitoring of blood glucose (SMBG) products, which is estimated to exceed $10 billion worldwide. Dario is a comprehensive system that combines an all-in-one SMBG device consisting of a lancet (to obtain a blood sample), a device-specific disposable test strip cartridge and a smartphone-driven glucose reader adaptor, with a smartphone app and cloud-based data services. LabStyle is pursuing patent applications in multiple jurisdictions covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services.

    Pressure Biosciences 10:40AM
    Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on our proprietary technology – pressure cycling technology. PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterrorism applications.

    Life Care Medical Devices 11:00 AM
    (LCMD)
    Life Care Medical Devices Limited engages in the production and distribution of medical device technologies. Its products include KeyHole Cup, a proprietary and PCT protected non-invasive device for use in laparoscopic surgery; and EPIOS pain management devices that are used to reduce or eliminate pain primarily on legs, arms, lower back, and shoulders through the emission of controlled and focused electrical signals.

    GlassesOff 11:20 AM
    GlassesOff is a healthcare software technology company, utilizing patented technology to develop and commercialize consumer-oriented software applications for improving visual functions. Our first product, scheduled for launch during Q3 2013, is a revolutionary pure-software applications for improving near vision sharpness, by improving the image processing function in the visual cortex of the brain, to eliminate the need for reading glasses.

    Cardax Pharmaceuticals 11:40 AM
    Cardax Pharmaceuticals is developing a platform of proprietary, exceptionally safe, small molecule compounds for large unmet medical needs where oxidative stress and inflammation play important causative roles. The Company’s platform includes CDX-085 with application in metabolic syndrome, arthritis, and cardiovascular disease, as well as other proprietary prodrugs for macular degeneration and prostate disease.

    CodeSmart 12:00 PM
    (FICF)
    CODESMART Group, Inc.  has the top ranked on-line school for ICD-10, CODESMART UNIVERSITY as the keystone of an integrated package of services, which provide a complete solution for ICD-10 conversions and revenue cycle integrity to healthcare organizations. CODESMART’s core focus is to furnish the healthcare industry with the best educated and qualified ICD-10 certified coders to close enormous talent shortage of over 3 million coders/billers created by ICD-10 over the next few years. CODESMART offers the only scalable and fully interactive on-line education program in ICD-10 for existing coders, practitioners, all healthcare roles, and importantly, new coders to satisfy the expected shortage of industry expertise.

    Lightlake Therapeutics 12:20 PM
    (LLTP)
    Lightlake Therapeutics Inc. is a London-based biopharmaceutical company using its expertise in opioid antagonists to build a platform of innovative solutions to common addictions and related disorders. The company holds many patents, including patents covering the use of intranasal naloxone to treat Binge Eating Disorder (“BED”) and Bulimia Nervosa (“BN”), as well as patents covering addiction to drugs, including cocaine, amphetamine, and MDMA. The company is currently focused on advancing its treatment for BED, which has successfully completed Phase II clinical trials, and a Phase II trial is planned for the indication of BN. The company is also applying its technology to develop a treatment for managing the complications of opioid drug addiction in collaboration with the National Institute on Drug Abuse, part of the National Institutes of Health. The company believes that revenues may be generated from this treatment within twelve to eighteen months.

    Millennium Healthcare Solutions 1:30 PM
    (MHCC)
    Millennium Healthcare Inc. is a market leader in providing innovative, state-of-the-art medical equipment, services and devices, with a focus on assisting the healthcare industry enhance, improve and better provide standards of reliability, safety and care.

    Amarantus Bioscience 1:50 PM
    (AMBS)
    Pioneering the development of a novel therapeutic protein that has neuron-protective properties – termed MANF – which has the potential to serve as a first-in-class treatment for neurological disorders that stops and/or reverses their debilitating effects. Importantly, MANF is also significantly cardiac-protective, providing Amarantus the ability to employ a two pronged drug development approach – a neurological disorder platform, and a heart disease platform.

    Cyto Wave Technologies 2:10PM
    Public Company Awaiting Ticker Symbol
    Developing a first-in-class medical device that allows the early detection, capture and targeted destruction of metastatic circulating cancer cells in vivo. The device is based on a laser technology that can identify and target metastatic cancer cells with 100-fold higher sensitivity than current assays. To date, the technology has been funded with US$4.4 million from the NIH, National Cancer Institute, and the Department of Defense. Company recently filed a Form 10 to register as a public company in Q2:2013.

    Greenestone Healthcare 3:30 PM
    (GRST)
    GreeneStone Healthcare Corp. operates medical clinics in Ontario, Canada. GreeneStone adds capacity to an increasingly stretched provincial healthcare system, and provides private alternatives to publicly underserviced niches. Its four medical clinics (three in Toronto, along with a facility in Muskoka, Ontario) offer various medical services, including addiction treatment, colonoscopy, endoscopy, minor cosmetic procedures, and executive health assessment programs. The company currently has more than 60 employees and is headquartered in Toronto.

     

     

  • Conference Info:

     

    Date: June 26-27, 2013
    Location: The Metropolitan Club, New York City


    Audience: Institutional investors, high net worth individual investors, family offices, business development executives throughout the US and Europe building and financing high growth medical technology, health care and life science companies.

    View the Schedule!

    View the Agenda!